Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 36%
Buy 60%
Hold 4%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. has demonstrated a robust expansion in gross margins, growing from the low 40s to approximately 60%, primarily driven by the increased clinical volume and higher average selling prices (ASPs) of key tests like Signatera. The company's revenue has nearly sextupled since 2019, indicating a strong financial foundation that supports further growth, especially in the sizeable $30 billion cancer screening total addressable market (TAM). With a growing Medicare Advantage reimbursement rate—from around 20% in the second half of 2023 to mid-to-high 60% by the end of 2024—alongside the introduction of new tests and enhanced market presence, Natera is well-positioned for sustained revenue growth and market leadership.

Bears say

Natera Inc is facing a challenging outlook due to weaker-than-expected fourth-quarter volumes primarily linked to disruptions from electronic medical record (EMR) integration and seasonal factors, which have raised concerns about its near-term revenue growth. Furthermore, the company's 2025 revenue guidance falls approximately $28.3 million below consensus, reflecting potential decreases in reimbursement for its products from payors, coupled with ongoing margin erosion due to pricing pressures in a competitive landscape. Additionally, any delays in clinical trial readouts or necessary reevaluations of product launch strategies could further hinder Natera's long-term revenue growth and profitability trajectory.

Natera (NTRA) has been analyzed by 25 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 60% recommend Buy, 4% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 25 analysts, Natera (NTRA) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.